[Featured Stock] Genexine Rises on Confirmation of Safety and Efficacy of 'Interleukin-7' for Severe COVID-19 Patients
[Asia Economy Reporter Minji Lee] Genexine is soaring on news that interleukin-7 (IL-7) has confirmed safety and efficacy in clinical trials targeting severe COVID-19 patients.
At 1:57 PM on the 27th, Genexine was trading at 175,400 KRW, up 16% from the previous session. The stock price even surged to 190,300 KRW during the session.
On this day, Genexine stated, "In recent clinical trials conducted in the UK targeting severe COVID-19 patients, interleukin-7 was confirmed to safely increase T cells without causing side effects such as cytokine storms. Additionally, the secondary infection rate was 58%, approximately 27 percentage points lower compared to patients who received only standard treatment without interleukin-7."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Trump Puts Attack on Hold, but "Only for a Certain Period"... Treasury Announces Sweeping Sanctions
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Meanwhile, Genexine's long-acting interleukin-7 (GX-I7) is currently undergoing clinical trials in the United States.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
